Seymour PICCOLO 2013.

Methods	Phase III open‐label, multicentre RCT; n = 1198 (460 participants in Arms A and B below)
Participants	Advanced inoperable colorectal cancer, progressed after fluoropyrimidine chemotherapy
Interventions	The combination of irinotecan and panitumumab (Arm A) vs irinotecan alone (Arm B)
Outcomes	Primary outcome: OS. Secondary endpoints: PFS, TRR, QoL, toxicity
Notes	Cancer Research UK ‐ independent peer review and feedback on protocols. Amgen ‐ provided panitumumab and educational grant. Follow‐up of participants still alive (n = 41): 25.4 months
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomisation was done with an automated telephonic system ... using a computer‐generated minimisation algorithm including a random element."
Allocation concealment (selection bias)	Low risk	Central computer‐generated randomisation after registration
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Open‐label trial but primary outcome (OS) not affected.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary endpoint of OS
Incomplete outcome data (attrition bias) All outcomes	Low risk	Equal dropout (4 withdrew in arm A, 4 in arm B)
Selective reporting (reporting bias)	Low risk	All secondary endpoints reported.
Other bias	Low risk	No other significant bias present; funders did not have inappropriate influence.